Genprex, Inc. 10-Q Summary
Business Context and Reporting Period
Genprex is a clinical-stage gene therapy company developing REQORSA for non-small cell and small cell lung cancer and GPX-002 diabetes gene therapies. The filing covers the three months ended March 31, 2024; financial statements are unaudited and prepared under U.S. GAAP.
- Acclaim-1: Phase 2a expansion enrolling patients with NSCLC after Tagrisso treatment; first patient enrolled and dosed in January 2024.
- Acclaim-2: Phase 1 dose escalation enrolling patients with NSCLC after Keytruda treatment.
- Acclaim-3: Phase 1 study of REQORSA plus Tecentriq for extensive-stage SCLC; the first patient was dosed in May 2024, after the reporting period.
- Diabetes programs remain in preclinical development.
Financial Position and Results
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $3.27 million | $5.31 million | Down 38% |
| General and administrative expense | $2.72 million | $3.95 million | Down 31% |
| Total operating expenses | $6.00 million | $9.26 million | Down 35% |
| Net loss | $5.97 million | $9.20 million | Down 35% |
| Basic and diluted net loss per share | $3.69 | $7.44 | Improved; per-share data reflect the 1-for-40 reverse split |
| Net cash used in operating activities | $5.30 million | $6.93 million | Down 24% |
| Cash and cash equivalents at period-end | $8.22 million | $18.08 million | Down 55% year over year |
No meaningful gross or operating margin is reported because the company has no revenue. Interest income was $27,713, compared with $68,471 in the prior-year quarter. The filing does not report outstanding debt; liabilities shown are current liabilities of $3.81 million, including $2.15 million of accounts payable.
Total assets were $12.56 million at March 31, 2024, including $2.53 million of research and development supplies. Accumulated deficit was $139.66 million. Cash exceeded FDIC insurance limits by approximately $7.97 million.
Material Changes Versus the Prior Comparable Period
- R&D expense declined $2.04 million, primarily because of lower manufacturing costs, reduced third-party R&D activity, lower headcount and lower related overhead.
- G&A expense declined $1.23 million because of lower headcount, professional-service costs and share-based compensation.
- Operating cash burn improved by $1.63 million, while financing proceeds increased by $2.71 million to $6.79 million.
- The company completed a March 2024 registered direct offering, receiving approximately $5.8 million net, and raised an additional $881,946 through its ATM facility.
- Common shares outstanding increased from 1,485,902 at December 31, 2023 to 1,922,586 at March 31, 2024. The company also had 3,358,191 warrants outstanding and 285,445 stock options outstanding, creating significant potential dilution.
- A 1-for-40 reverse stock split became effective February 2, 2024; historical share and per-share data were retrospectively adjusted.
Liquidity, Outlook, Risks and Unusual Items
- Management estimates that existing cash will fund current operations and planned clinical activities into the third quarter of 2024.
- The company has recurring losses, no current revenue source and expects to require additional equity, debt, ATM or strategic financing. Management states that substantial doubt exists regarding the company’s ability to continue as a going concern.
- Clinical objectives include completing Acclaim-1 cohort enrollment by the end of 2024, completing Acclaim-2 dose escalation in the second half of 2024, and starting the Acclaim-3 Phase 2 expansion in the second half of 2024. Acclaim-1 interim analyses are expected in early 2025.
- Clinical, regulatory, manufacturing, enrollment, intellectual-property, financing, competition and Nasdaq listing risks could delay or prevent commercialization. The company depends substantially on third-party manufacturers and research providers.
- Material weaknesses in internal control over financial reporting remain, involving segregation of duties and insufficient in-house accounting expertise. Remediation is underway but has not been demonstrated to be effective for a sufficient period.
- After quarter-end, former CEO and Chairman Rodney Varner died on May 7, 2024. Ryan Confer was appointed President and CEO while continuing as CFO, and the board began searching for a permanent CFO.
- The company reports no material pending litigation. License and research commitments include approximately $2.9 million under the MD Anderson sponsored research agreement, approximately $4.5 million under a manufacturing agreement, and milestone obligations under University of Pittsburgh licenses; many payments are contingent or scheduled over time.
Important Facts for Investors to Verify
- Whether additional financing is secured before the projected third-quarter 2024 cash runway expires.
- Actual enrollment, safety and efficacy results for Acclaim-1, Acclaim-2 and Acclaim-3 versus stated timelines.
- The dilutive impact of 3.36 million outstanding warrants, 285,445 options, pre-funded warrants and future ATM sales.
- Progress in remediating the material weaknesses in internal controls and the effect of the CEO/CFO transition.
- Cash concentration exposure above FDIC insurance limits and the company’s continuing-going-concern disclosure.
- Whether clinical manufacturing, regulatory guidance and third-party supply arrangements remain on schedule and within available funding.